Webinar: eCTD Submission Different Strategies: In-house vs. Outsourcing
eCTD Submission Strategies, including outsourcing, are influenced by varying requirements in various regions and countries. That and diverse technical resources by companies often lead to various regulatory strategies. Thus, the questions arises: how to choose the best tactics for eCTD submission that your needs?
The purpose of this webinar is to discuss the different approaches to prepare eCTD submissions, its requirements, technical resources, and process validation.
You will learn about:
1. Requirements for eCTD
- Different forms of eCTD used in EU vs. EAEU eCTD
- Legislation framework
- Regions and countries following the eCTD
2. Different approaches to prepare eCTD submissions: In-house vs. Outsourcing
- Advantages of eCTD submission outsourcing strategies vs. in-house management:
- Optimization of resources with proper experience
- Increased business continuity
- Cost optimization
3. Technical resources
- Software and networks
- Document and project management
- Potential challenges
4. How to validate submission to achieve compliance and high quality
- Tips and tricks
Registering a new product?
Make use of our experts to enter new markets. Explore your options in an informal chat with one of our experts.
Who Should Attend? Professionals from the following fields:
- Regulatory Managers
- Regulatory Strategy Managers
- RA Partnerships Operations Manager
- QA Managers supporting RA
- RA Healthcare Compliance Managers
Duration: 25 min.
Speaker: Head of Global Regulatory Affairs, Olga Bernardova, MSc, who will share her expertise regarding eCTD submissions.
Olga Bernardova, MSc
Head of Global Regulatory Affairs
Other content that might interest you:
Saudi FDA’s New Pricing Guidelines and Impact on the Region
In a highly evolving regional pricing environment, Saudi Arabia (KSA) is no exception. The Saudi Food and Drug Authority (SFDA) has been periodically reviewing its pricing mechanisms and criteria so that the country becomes a regional reference for the prices of pharmaceutical products. What followed is a change in the pricing strategy by SFDA and a shift from price takers to price makers.
Marketing pharmaceutical products in CIS countries / Eurasion Union
The interest of pharmaceutical companies in expanding business across CIS region has been constantly growing. For the same reason, Biomapas has expanded presence and now covers the whole CIS region, providing core services: clinical research, regulatory affairs,...
Regulatory Strategy in the EAEU and rest of CIS Countries
Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of...
